English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Aim. To analyze the expression of the p53 and Ki67 markers in patients with stage IIIC-IV ovarian cancer by immunohistochemical (IHC) method as a criterion for the treatment effectiveness. Materials and Methods. The study included 93 patients with ovarian cancer stage IIIC-IV aged 34-77 years. The patients were divided into 4 groups: group 1 – with neoadjuvant chemotherapy and intramuscular injections of recombinant interferon-gamma; group 2 – with neoadjuvant chemotherapy and intraperitoneal injections of recombinant interferon-gamma; group 3 (controls) – standard chemotherapy without interferon-gamma; group 4 (comparison group) – with surgery  as the first stage of treatment. All tumor samples were studied by IHC method for the expression of p53 protein and Кi-67 marker of proliferative activity.  Results. Neoadjuvant chemotherapy did not affect the levels of p53, compared to the group  without chemotherapy. Inclusion of interferon-gamma to neoadjuvant chemotherapy resulted in statistically significant decrease in p53 expression, mainly with intraperitoneal administration. Study of proliferative potential of tumors in patients with intraperitoneal injections of interferon-gamma showed 1.3 times higher predomination of tumors with low proliferative activity com-pared to patients with intramuscular administration, 3.5 times higher compared to the group re-ceiving chemotherapy without interferon-gamma, and 7 times higher than in patients with sur-gery. High proliferative activity was noted only in tumor cells of patients without neoadjuvant chemotherapy.  Conclusions. The IHC study demonstrated that inclusion of interferon-gamma to chemotherapy decreases proliferative potential of tumors and expression of р53 by tumor cells in ovarian cancer patients, especially with intraperitoneal introduction in the course of neoadjuvant chemotherapy.

nauka molodyh

CHARACTERISTICS OF EXPRESSION OF SOME IMMUNOHISTOCHEMICAL MARKERS IN PATIENTS WITH STAGE IIIC-IV OVARIAN CANCER AS A CRITERION OF EFFECTIVENESS OF CHEMOIMMUNOTHERAPY